Renalytix plc

("Renalytix" or the "Company")

Grant of Share Options

LONDON and SALT LAKE CITY - July 6, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA approved artificial intelligence (AI) enabled prognostic blood test for individuals with Type 2 diabetes and chronic kidney disease, announces that its Remuneration Committee have granted options over a total of 2,473,296 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to the following individuals:

The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £1.025 per ordinary share, being the closing price of the shares on the 5 July 2023.  

All the Share Options bar those granted to Catherine Coste vest as follows: one twelfth of the Share Options vest 3 months from the date of grant with one twelth vesting quarterly after that, subject to the individuals remaining employed by the Company.

The Share Options granted to Catherine Coste vest as follows: one third of the Share Options vest 12 months from the date of grant with one eight vesting quarterly after that, subject to Ms. Coste remaining a Non-Executive Director of the Company.

The issue of the Share Options to James McCullough, Oliver Sterling, Fergus Fleming, Thomas McLain and Catherine Coste are deemed to be related party transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The Company's directors (excluding those who are being awarded the Share Options) consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe Limited, that the terms of the related party transactions are fair and reasonable insofar as the shareholders of the Company are concerned.

For further information, please contact:

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX technology platform to introduce novel laboratory developed and FDA approved tests to enable risk assessment and appropriate care management in adult patients with type 2 diabetes and early-stage CKD. By gaining early visibility into risk for progressive decline in kidney function, and an understanding of associated actionable insights, patients and health care providers may benefit from improved outcomes and decreased costs. For more information, visit our Company website at www.renalytix.com and our product website at www.kidneyintelx.com.

About KidneyIntelX™

KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable, bioprognostic™ methodology that yields a simple-to-understand, custom risk score, enabling prediction of which adult patients with T2D and early CKD (stages 1-3) are at low, intermediate or high risk for rapid progressive decline in kidney function. By combining information from KidneyIntelX with newer cardio - and reno-protective therapies, doctors will have more information in determining which patients are at higher versus lower risk for rapid disease progression and may be able to more appropriately target resources and guideline-recommended treatments to advance kidney health. KidneyIntelX is supported by a growing body of clinical, utility and health economic studies (including a validation study of two large cohorts) and has demonstrated a 72% improvement in predicting those patients who are at high risk for rapid progressive decline in kidney function versus the current standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough Device Designation from the U.S. Food and Drug Administration and Renalytix has submitted for De Novo marketing authorization. To learn more about KidneyIntelX and review the evidence, visit www.kidneyintelx.com.